bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.97 USD
+0.01 (0.53%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $0.96 -0.01 (-0.88%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Bluebird Bio (BLUE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.07 | $8.00 | $1.00 | 323.96% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Bluebird Bio comes to $4.07. The forecasts range from a low of $1.00 to a high of $8.00. The average price target represents an increase of 323.96% from the last closing price of $0.96.
Analyst Price Targets (10)
Broker Rating
Bluebird Bio currently has an average brokerage recommendation (ABR) of 2.62 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 2.57 a month ago based on 14 recommendations.
Of the 13 recommendations deriving the current ABR, four are Strong Buy, representing 30.77% of all recommendations. A month ago, Strong Buy made up 28.57%, while Buy represented 7.14%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 1 | 1 | 0 |
Hold | 7 | 7 | 7 | 7 | 7 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.62 | 2.62 | 2.57 | 2.57 | 2.62 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/9/2024 | William Blair | Sami Corwin | Hold | Hold |
3/19/2024 | Wedbush Securities | David M Nierengarten | Hold | Hold |
3/8/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Hold | Hold |
12/12/2023 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
11/7/2023 | SVB Securities | Mani Foroohar | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.62 |
ABR (Last week) | 2.62 |
# of Recs in ABR | 13 |
Average Target Price | $4.07 |
LT Growth Rate | 26.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 87 of 252 |
Current Quarter EPS Est: | -0.50 |